載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.1782
−US$0.0364 · -16.96%
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
前收盤價
US$0.1782
−US$0.0364 · -16.96%
盤後
US$0.18
+US$0.0018 · +1.01%
10月12日 下午7:50 ET
盤中時間採用ET。市場資料可能有所延遲。
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
日內區間
目前US$0.1782
52週區間
目前US$0.1782
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
43
合理估值
情緒
53
多空交錯
風險
63
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
日內區間
目前US$0.1782
52週區間
目前US$0.1782
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 714萬 USD | 581.5萬 USD | 370.8萬 USD | 322.6萬 USD | — |
| 銷售、一般及管理費用 | 447.8萬 USD | 673.1萬 USD | 92.8萬 USD | 57.7萬 USD | 94.39萬 USD |
| 營業費用 | −1163.2萬 USD | 1257.1萬 USD | 468.1萬 USD | 386萬 USD | 94.39萬 USD |
| 利息收入 | 14.2萬 USD | 1000 USD | 15.3萬 USD | 11.4萬 USD | 6372 USD |
| 利息支出 | 1.3萬 USD | 5.2萬 USD | 9000 USD | 8.5萬 USD | — |
| 折舊和攤銷 | 1.4萬 USD | 2.5萬 USD | 4.5萬 USD | 5.7萬 USD | — |
| 營業利益 | 1163.2萬 USD | −1257.1萬 USD | −468.1萬 USD | −386萬 USD | −94.39萬 USD |
| 淨利 | −1191.2萬 USD | −1644.3萬 USD | −494.2萬 USD | −321.5萬 USD | −75.52萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年5月29日 | 1:10 | — | — |
股票分割 | 2025年7月29日 | 1:15 | — | — |
股票分割 | 2024年11月29日 | 1:9 | — | — |
已生效 2026年5月29日
1:10
已生效 2025年7月29日
1:15
已生效 2024年11月29日
1:9
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
